// App-Quantinova.ai

P370 : Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase 3 study U ACHIEVE maintenance

Researchers

Presenter

  • Pans, J

Principal Investigators

  • Loftus, E.V.J

  • Higgins, P

  • Lindsay, J.O

  • Zhou, W

  • Yao, X

  • Ilo, D

  • Phillips, C

  • Tran, J

  • Sanchez Gonzalez, Y

  • Vermeire, S

Medical Centers

  • Hospital Clinic Barcelona- IDIPABS- CIBERehd- Barcelona- Spain, n/a, Barcelona, Spain

  • Mayo Clinic College of Medicine, Rochester, Minnesota, United States

  • University of Michigan, n/a, Ann Arbor, United States

  • The Royal London Hospital, Barts Health NHS Trust, Department of Gastroenterology, London, UK

  • AbbVie Inc., n/a, North Chicago, United States

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

Locations

  • Spain

  • United States

  • United Kingdom

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Genetic Disorder

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

Biomarkers

  • Plasminogen Activator, Urokinase

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved